来源：新浪基金 2、龙头占比大。前十大创新药龙头权重超73%，表征创新药硬核力量。 3、风险更可控。对流动性较差的成份股强制降权，有力管控尾部风险。 | | | 港股通创新药ETF (520880) 标的指数 | | | --- | --- | --- | --- | | | | 前十成份股权重高达73.41%,龙头优势显著 | | | 46.65 | 简称 | 权重(%) | 总市值(亿港元) | | 9926.HK | 康定物 | 10.49 | 1,109 | | 6160.HK | 百济神州 | 10.01 | 3,120 | | 1093.HK | 石药集团 | 9.97 | 1,021 | | 1177.HK | 中国生物制药 | 9.47 | 1,234 | | 1801.HK | 信达生物 | 9.38 | 1,454 | | 3692.HK | 朝森制药 | 8.15 | 2,336 | | 1530.HK | 三生制药 | 7.13 | 666 | | 6990.HK | 科伦博泰生物-B | 4.01 | 1,028 | | 0867.HK | 康哲药业 | 2.55 | 333 | | ...

1月8日早盘，港股延续调整，创新药再度逆市领涨！纯度100%的港股通创新药ETF（520880）连续第4 日上涨，高开后再度冲上2%，一举站上60日线！成份股映恩生物-B涨超6%居首，和黄医药涨超4%。 | | | 分时 多日 1分 5分 15分 30分 60分 日 周 · | | | | | | F9 盘前盘后 盛加 九转 西氏 工具 @ 0 | > | 港股通创新药ETF O | | 520880 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.556 | | | | | 520880JA股通创新资ETF] 09:58 价 0.555 涨跌 0.011(2.02%) 均价 0.553 股交盘 9.51万 IOPV 0. | | | | 2.59% | 0.555 | | +0.011 +2.022 | | 0.553 July 1 | | | | | | | | | 1.7393 | SSE CNY 9:58:33 文理中 | | T+0 图 / 图 + | | | | | | | ...

登录新浪财经APP 搜索【信披】查看更多考评等级 | | | 1月7日重要公告摘要 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 今日聚焦 | | | | | 新宏泽 锋龙股份 | 副董事长孟学自愿放弃领取薪酬 如股票价格进一步异常上涨可能申请停牌核查 | | | 振芯科技 | 控股子公司因串通投标等违规行为3年内被禁止参加西部战区的采购活 | | | *ST阳光 | 控股股东筹划控制权变更事项 股票停牌 | | | 洲明科技 | 子公司获配智谱6.69万股H股 获配金额77.38万港元 | | | 思泉新材 | 第四大股东吴攀拟减持不超1.79%股份 | | | 口子窖 | 2025年净利同比预降50%-60% 核心利润来源高端客产品销量大幅下滑 | | | 中集集团 | 联营公司出售物业预计减少公司归母净利润约11亿元 | | | 南京能猫 | 尚无与脑机接口相关的成熟产品 亦未形成相关销售收入 | | | 可川科技 | 子公司可川光子已建成光模块产能 硅光芯片已完成首次流片但暂未邢 | | | 北方导航 | 在商业航天领域无相关业务和订单 | | | 北斗星通 | ...

证券日报网讯 1月7日，信立泰发布公告称，公司自主研发的siRNA创新药SAL0145注射液临床试验申请 获国家药监局受理，拟用于MASH治疗，若获批将丰富慢病领域的创新产品管线。 （文章来源：证券日报） ...

Group 1 - Yili Co., Ltd. announced that Chairman Pan Gang plans to reduce his holdings by up to 62 million shares, accounting for 0.98% of the company's total share capital, to repay stock pledge financing loans [1] - New Hongze's Vice Chairman Meng Xue voluntarily waived his salary, including a basic annual salary of 1.07 million yuan, to focus on the company's strategic decisions and long-term development [2] - Guangqi Technology's subsidiary signed contracts totaling 264 million yuan for the mass production of metamaterials with four clients, with expected delivery by December 31, 2026 [3] Group 2 - Zhuhai Ming Technology's subsidiary received an allocation of 66,900 H-shares from Zhipu, amounting to 7.77 million Hong Kong dollars [4] - Chengdi Xiangjiang announced that the revenue from the construction of two data center buildings will decrease by approximately 1.09 billion yuan due to changes in business conditions [5] - Siquan New Materials' shareholder Wu Pan plans to reduce his holdings by up to 1.79% of the company's shares due to personal funding needs [6] Group 3 - Zhenxin Technology's subsidiary was banned from participating in procurement activities in the Western Theater for three years due to collusion in bidding [8] - Xinlitai's innovative drug SAL0145 injection clinical trial application has been accepted by the National Medical Products Administration, targeting MASH treatment [9] - Hengrui Medicine's innovative drug Ruira Fup α injection has been approved for market launch, with no similar products approved domestically or internationally [10] Group 4 - Baoneng New Energy's actual controller was fined 12 million yuan and had illegal gains of 25.54 million yuan confiscated due to violations of information disclosure [11] - Beidou Star Communication announced that several directors and executives plan to reduce their holdings by a total of 0.012% of the company's shares due to personal funding needs [12] - Pulit announced that its LCP film technology has a high barrier to entry and is the only domestic company to achieve breakthroughs in this technology, with ongoing clinical trials for brain-machine interface applications [13]

格隆汇1月7日丨信立泰(002294.SZ)公布，收到国家药品监督管理局核准签发的受理通知书，公司自主 研发的创新药SAL0145注射液（项目代码：SAL0145）临床试验申请获得受理。代谢功能障碍相关脂肪 性肝炎（MASH）是代谢功能障碍相关脂肪性肝病（MASLD）的进展形式之一，后者累及全球约30% 成年人口。若不加以干预或治疗，MASH会进一步发展为肝硬化甚至肝癌，对患者的生命健康造成威 胁。临床前研究显示，SAL0145具有治疗MASH的潜力，若能研发成功并获批上市，将有望为患者提供 新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。 ...

智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的受理通知书，公司 自主研发的创新药SAL0145注射液(项目代码：SAL0145)临床试验申请获得受理。 公告显示，SAL0145是公司研发的具有自主知识产权的siRNA药物，公司本次提交的申请为SAL0145用 于治疗MASH的临床试验申请。 ...

信立泰（002294）(002294.SZ)公告，公司收到国家药品监督管理局核准签发的受理通知书，公司自主 研发的创新药SAL0145注射液(项目代码：SAL0145)临床试验申请获得受理。 公告显示，SAL0145是公司研发的具有自主知识产权的siRNA药物，公司本次提交的申请为SAL0145用 于治疗MASH的临床试验申请。 ...

信立泰公告，近日，公司自主研发的创新药SAL0145注射液（项目代码：SAL0145）临床试验申请获得 受理。SAL0145是公司研发的具有自主知识产权的siRNA药物，公司本次提交的申请为SAL0145用于治 疗MASH的临床试验申请。 ...